Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP313704.RA57Jazf6e2WIjKaJuw-sNUL8WsZTPtW_P-SnAEST_bjo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP313704.RA57Jazf6e2WIjKaJuw-sNUL8WsZTPtW_P-SnAEST_bjo130_assertion type Assertion NP313704.RA57Jazf6e2WIjKaJuw-sNUL8WsZTPtW_P-SnAEST_bjo130_head.
- NP313704.RA57Jazf6e2WIjKaJuw-sNUL8WsZTPtW_P-SnAEST_bjo130_assertion description "[Liver transplant recipients with recurrent HCV (elevated serum aminotransferases, positive serum HCV RNA, and biopsy-proven hepatitis without rejection) received interferon-alpha (1.5-3 million units subcutaneously three times a week) and ribavirin (400-1000 mg p.o.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP313704.RA57Jazf6e2WIjKaJuw-sNUL8WsZTPtW_P-SnAEST_bjo130_provenance.
- NP313704.RA57Jazf6e2WIjKaJuw-sNUL8WsZTPtW_P-SnAEST_bjo130_assertion evidence source_evidence_literature NP313704.RA57Jazf6e2WIjKaJuw-sNUL8WsZTPtW_P-SnAEST_bjo130_provenance.
- NP313704.RA57Jazf6e2WIjKaJuw-sNUL8WsZTPtW_P-SnAEST_bjo130_assertion SIO_000772 11292302 NP313704.RA57Jazf6e2WIjKaJuw-sNUL8WsZTPtW_P-SnAEST_bjo130_provenance.
- NP313704.RA57Jazf6e2WIjKaJuw-sNUL8WsZTPtW_P-SnAEST_bjo130_assertion wasDerivedFrom befree-2016 NP313704.RA57Jazf6e2WIjKaJuw-sNUL8WsZTPtW_P-SnAEST_bjo130_provenance.
- NP313704.RA57Jazf6e2WIjKaJuw-sNUL8WsZTPtW_P-SnAEST_bjo130_assertion wasGeneratedBy ECO_0000203 NP313704.RA57Jazf6e2WIjKaJuw-sNUL8WsZTPtW_P-SnAEST_bjo130_provenance.